Phase 1 N=150 N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Coronavirus · Covid19
Primary: Number of Participants Intubated During Hospitalization — 8; 25 Participants — p=0.297
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
C3 Glomerulopathy · C3 Glomerulonephritis · Dense Deposit Disease
Primary: Change From Baseline In Composite Biopsy Score At Week 28 — 11.7; 9.3; 9.2; 10.7 score on a scale
N/A N=6 Apraxia of Speech: Comparison of EPG Treatment (Tx) and Sound Production Treatment (SPT)
Apraxia of Speech · Aphasia, Acquired · Speech Disorders
Primary: Speech Production: Percent Change in Treated Items Immediately Post Treatment — 59; 66 % change
N/A N=63 Tanglewood Trail Walking Program in Rural Kentucky 2019
Dietary Habits
Primary: Carotenoid Levels — 148.7; 176.4 relative units (absorbance)
N/A N=114 Improving Adherence to Cognitive Rehabilitation
Psychosis
Primary: Number of Sessions Attended — 7.70; 4.98 sessions — p=0.24
Phase 2 N=102 A Trial of Tisotumab Vedotin in Cervical Cancer
Cervical Cancer
Primary: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) — 23.8 Percentage of Participants — p=0.0002
N/A N=60 Survival of Endocrowns Made From Different Ceramics
Pulp Disease, Dental · Dental Caries · Dental Leakage
Primary: Survival of Dental Prosthesis — 19; 14; 17 Teeth
Phase 3 N=499 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Primary: Overall Survival (OS) — 10.9; 10.4 months — p=0.1779
N/A N=2,647 Preventing Sexual Violence Through a Comprehensive, Peer-led Initiative
Sexual Violence
Primary: Number of Participants Reporting Any Form of Sexual Violence Perpetration — 5; 54; 2; 57 Participants
Phase 2 N=25 A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
Jet Lag Disorder
Primary: Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted — 76.2; 41.4 minutes — p=0.0354
N/A N=120 Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema
Emphysema
Primary: Percent Change in FEV1 at 6 Months — 12.745; -2.604 percent change from baseline
Phase 1 N=19 A Pharmacokinetic Study of PLENVU® in Healthy Subjects
Pharmacokinetic
Primary: Tmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) — 3.00; 9.00; 5.00 hours
Phase 1 N=36 Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
HSV · Herpes Labialis
Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)
Phase 2 N=41 Biology and Experience of Eating in Women With Obesity
Obesity
Primary: Number of Participants Who Reported Nausea at 10 Minutes Post Treatment — 17; 18 Participants
Phase 3 N=614 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
Anaemia
Primary: Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28) — 0.19; 1.58 Grams per deciliter — p=<0.0001